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Introduction {#sec1}
============

Tissue resident macrophages are essential for tissue homeostasis and are in turn modulated by tissue factors. Alveolar macrophages (AMs) show a high capacity for self-maintenance by local proliferation ([@bib17]), with little repopulation by blood-circulating monocytes in the steady state ([@bib5], [@bib7]). Mature AMs regulate surfactant levels in the lung ([@bib1], [@bib13], [@bib19]). Factors including granulocyte-macrophage colony-stimulating factor (GM-CSF) (*Csf2*^*−/−*^), GM-CSF receptor (*Csf2rb*^*−/−*^) ([@bib13], [@bib19]), PPAR-γ ([@bib15]), and mammalian target of rapamycin (mTOR) ([@bib18]) are required for AM development and function.

Initial lung development occurs in a relatively hypoxic environment, beginning in mice on embryonic day 9 (E9) ([@bib9]). Fetal monocytes colonize the developing lung at approximately E12.5 and E16.5 and only differentiate into mature AMs after birth ([@bib5]). Epithelial cell-derived GM-CSF is essential for the early commitment of AM precursors ([@bib5], [@bib15]). However, it remains unknown whether AM adaptation to increased oxygen concentration in the postnatal lung influences AM maturation and function.

We hypothesized that sensing the increased oxygen concentration just after birth may be important for postnatal AM maturation. Hypoxia-inducible transcription factors (HIFs) are the master regulators of the transcriptional response to low oxygen tensions, and HIF depletion affects macrophage physiology ([@bib8], [@bib10], [@bib12]). Under normoxia, HIF-α subunits are hydroxylated and bind to the Von Hippel-Lindau tumor suppressor protein (VHL), which is part of an E3 ubiquitin ligase complex targeting HIF-α subunits for proteasomal degradation. Therefore, *Vhl* deletion induces normoxic expression of HIF target genes ([@bib4], [@bib12]). Here, we deleted *Vhl* in the CD11c^+^ compartment (CD11cΔ*Vhl*) to desensitize AMs to oxygen after birth. *Vhl* deletion induced the expression of HIF target genes and altered the AM metabolic profile. VHL-deficient AMs showed an immature-like phenotype and a decreased self-renewal capacity that were cell intrinsic, as demonstrated using mixed bone marrow (BM) chimeras. In addition, VHL contributed to AM-mediated surfactant clearance in a model of alveolar proteinosis. Our results therefore support the notion that intact oxygen-sensing capacity is required for AM terminal differentiation, self-renewal, and function.

Results and Discussion {#sec2}
======================

Downregulation of Hypoxia and Glycolysis during Postnatal AM Maturation {#sec2.1}
-----------------------------------------------------------------------

To explore whether oxygen sensing by AMs could be linked to their maturation, we analyzed a publicly available microarray data ([@bib15]) containing the transcriptional profile of AMs from pups at postnatal days 2 and 11 and from adult mice that were 8--12 weeks old. Gene set enrichment analysis (GSEA) was performed on the gene expression profiles using the hallmark collection of the Molecular Signatures Database (MSigDB). Results showed significant enrichment of both hypoxia and glycolysis gene sets in immature AMs from 2-day-old pups compared with mature AMs from adults ([Figure 1](#fig1){ref-type="fig"}A). In addition, the expression of core genes from these two enriched hallmark gene sets was gradually downregulated during AM maturation ([Figure 1](#fig1){ref-type="fig"}B), suggesting postnatal adaptation of AMs to oxygen. Core genes from both gene sets included well-known HIF targets such as Slc2a1, Hk2, Pdk1, and Slc2a3 ([Figures 1](#fig1){ref-type="fig"}B and 1C \[genes marked in red\]). Analysis of other classical HIF target genes in most cases revealed the same expression dynamics ([Figures 1](#fig1){ref-type="fig"}C and 1D). The mean expression of all HIF target genes was thus significantly higher in immature AMs (day 2) than in mature AMs from adult mice, whereas no significant changes were found between postnatal day 11 and adulthood ([Figure 1](#fig1){ref-type="fig"}E), correlating with the end of AM terminal differentiation at approximately postnatal day 7 ([@bib5]). These results suggest that downregulation of HIF activity in AMs upon exposure to high oxygen tension after birth may be important for AM terminal differentiation, concurring with the HIF-1-independent role of mTOR in AM development after birth ([@bib18]).Figure 1Downregulation of Hypoxia and Glycolysis during Postnatal AM Maturation(A) Enrichment plots from GSEA of postnatal day 2 (D2) compared with adult (AD) AMs using the hallmark gene set collection from the Molecular Signatures Database (MSigDB).(B) mRNA expression (normalized log~2~, robust multiarray average \[RMA\] counts) of core genes from hypoxia and glycolysis gene sets in lung AMs from postnatal day 2 (D2), D11, and adult mice. Red and blue represent overexpressed and underexpressed genes, respectively.(C) Table depicting some classic HIF target genes. Genes marked in red are present in [Figure 1](#fig1){ref-type="fig"}B.(D) mRNA expression (as seen in [Figure 1](#fig1){ref-type="fig"}B) of HIF target genes not included in the hallmark gene sets indicated in [Figure 1](#fig1){ref-type="fig"}B (marked in black); color intensity defined as seen in [Figure 1](#fig1){ref-type="fig"}B.(E) Expression of HIF target genes from [Figure 1](#fig1){ref-type="fig"}C in D2 and D11 AMs. Values represented as the ratio of the mean expression in AMs from D2 or D11 mice into the mean expression in AMs from adult mice. ns, not significant; ^∗∗^p \< 0.01 by column statistics analysis, hypothetical value = 1.

Lack of VHL Results in AM-Immature Phenotype and Modified Metabolic Profile {#sec2.2}
---------------------------------------------------------------------------

To investigate the biological significance of oxygen-sensing modulation in AMs after birth, we generated a genetic system to prevent HIF degradation in response to high postnatal oxygen pressures by deleting *Vhl* in the CD11c lineage (CD11c-Cre *Vhl*^fl/fl^ mice). Compared to the LysM(*Lyz2*)-Cre driver, the CD11c-Cre driver specifically targets postnatal AMs ([@bib5]). *Vhl* deletion leads to an increased glycolytic activity of macrophages under basal conditions ([@bib4]). Sorted bronchoalveolar lavage (BAL) AMs from CD11c-Cre^+^ *Vhl*^fl/fl^ (CD11cΔ*Vhl*) mice showed decreased *Vhl* mRNA levels relative to AMs from CD11c-Cre^−^ *Vhl*^fl/fl^ littermates (control *Vhl*^fl/fl^) ([Figure 2](#fig2){ref-type="fig"}A). *Vhl* deletion in AMs resulted in the increased expression of HIF-1 targets such as *Ldha* (lactate dehydrogenase) ([@bib16]), HIF-2 targets such as *Arg1* (arginase 1) ([@bib22]), and common HIF-1 and HIF-2 target genes such as *Slc2a1* (glucose transporter 1) ([@bib3]) ([Figure 2](#fig2){ref-type="fig"}B). To explore the functional consequences of *Vhl* deletion in AMs, we conducted an RNA sequencing (RNA-seq) analysis to compare the transcriptome of BAL AMs isolated from CD11cΔ*Vhl* and control *Vhl*^fl/fl^ mice. GSEA showed significant enrichment of hypoxia and glycolysis gene sets from the hallmark collection in the absence of VHL ([Figure 2](#fig2){ref-type="fig"}C), resembling the comparison of day 2 postnatal versus adult AMs ([Figure 1](#fig1){ref-type="fig"}A) and indicating that, at the transcriptional level, the absence of VHL affects the ability of AMs to detect oxygen. To address this influence functionally, we determined the real-time metabolic profile of AMs from BAL. The absence of VHL in AMs significantly decreased their basal respiratory rate (BRR) ([Figures 2](#fig2){ref-type="fig"}D and 2E) while increasing their basal extracellular acidification rate ([Figure 2](#fig2){ref-type="fig"}F). These results indicate that the deletion of VHL in AMs induces the expression of HIF-1 and HIF-2 target genes and alters their basal metabolic profile.Figure 2Deletion of VHL Alters AM Metabolic Profile and Phenotype(A and B) Mean expression of *Vhl* (A), *Ldha*, *Arg1*, and *Slc2a1* (B) by qPCR in sorted BAL AMs from the indicated genotypes. Data represent four pools of mice corresponding to four independent experiments. n = 4--5 mice per genotype. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 by ratio paired Student's t test.(C) Enrichment plots from GSEA analysis of CD11cΔ*Vhl* (knockout \[KO\]), compared with control *Vhl*^fl/fl^ (wild-type \[WT\]) AMs using the hallmark gene set collections as seen in [Figure 1](#fig1){ref-type="fig"}B.(D) Oxygen-consumption rate (OCR) by BAL AMs in the presence of glucose, glutamine, and pyruvate sequentially treated with oligomycin (Oligo), carbonyl cyanide m-chlorophenylhydrazone (CCCP) and rotenone+antimycin (Rot+Ant). Data are means ± SDs and are representative of four independent experiments. n = 6--7 mice per genotype.(E and F) Basal respiratory rate (BRR) (E) and basal extracellular acidification rate (ECAR) (F) of BAL AMs. Data represent four independent experiments. n = 6--7 mice per genotype. ^∗^p \< 0.05 by ratio paired Student's t test.(G--I) Morphological parameters of BAL AMs from each genotype after 5-day culture in complete medium. Representative images of H&E staining (error bars, 50 μm) (G), mean AM size ± SEM (H), and mean AM circularity ± SEM (I). Data are representative of two independent experiments. n = 4--5 mice per genotype. ^∗∗∗^p \< 0.001, by unpaired Student's t test.(J) Expression of *Itgax*, *Siglec5*, *Fcgr1*, and *Itgam* by qPCR as in (A) and (B). ^∗^p \< 0.05, ^∗∗^p \< 0.01 by ratio paired Student's t test.(K) Representative flow cytometry histograms for CD11c, Siglec-F, CD64, and CD11b (black line) expression compared with unstained samples (blue) in BAL AMs from the indicated genotypes.(L) Normalized geometric mean fluorescence intensity (GMFI) for markers from [Figure 2](#fig2){ref-type="fig"}K. Data shown as means ± SEMs and representative of three experiments. n = 6--7 per genotype. ^∗∗∗^p \< 0.001 by unpaired Student's t test.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Altered AM terminal differentiation can lead to the development of AM-like cells with a distorted phenotype ([@bib15]). We found that VHL-deficient AMs from BAL were smaller and unable to acquire the fusiform morphology of control *Vhl*^fl/fl^ AMs after culture *ex vivo* for 5 days, instead maintaining a rounded shape that is similar to that of precursor cells or monocytes ([Figures 2](#fig2){ref-type="fig"}G--2I) ([@bib5]). Because altered maturation can affect AM phenotype ([@bib15]), we measured the expression of canonical surface markers on BAL AMs *ex vivo*. VHL-deficient AMs slightly reduced mRNA for *Itgax* (CD11c) without affecting membrane receptor expression ([Figures 2](#fig2){ref-type="fig"}J--2L). Notably, VHL-deficient AMs showed decreased mRNA and protein for *Siglec5* (Siglec-F) and *Fcgr1a* (CD64), whereas *Itgam* (CD11b) was increased ([Figures 2](#fig2){ref-type="fig"}J--2L). This phenotype is linked to an immature AM state ([@bib5], [@bib15]).

Although access to the alveolar niche is restricted in steady-state conditions, blood monocytes can access the lung alveoli and differentiate into AMs under specific conditions ([@bib7]). Thus, the immature-like phenotype of VHL-deficient AMs could be either cell intrinsic or caused by increased infiltration of monocytes in CD11cΔ*Vhl* mice. To investigate this, we performed surgical parabiosis of CD45.1 wild-type (WT) mice with either CD45.2 control *Vhl*^fl/fl^ or CD11cΔ*Vhl* mice ([Figure S1](#mmc1){ref-type="supplementary-material"}A). After 30 days, analysis of the peripheral blood in CD45.2 parabionts revealed equivalent frequencies of CD45.1^+^ neutrophils and Ly6C^hi^ monocytes, found at the same level as those exchanged after longer protocols of parabiosis in the steady state ([@bib7]) ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). Lung CD45.1^+^ Ly6C^hi^ monocytes and BAL AMs frequencies were similar in both genotypes ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). These results suggest that the immature-like phenotype of VHL-deficient AMs is caused by a cell-autonomous effect and is not a consequence of differential lung infiltration by monocytes.

Cell-Cycle Regulation and Lipid Handling Are Altered in VHL-Deficient AMs {#sec2.3}
-------------------------------------------------------------------------

RNA-seq identified 2,531 differentially expressed genes in CD11cΔ*Vhl* AMs relative to control *Vhl*^fl/fl^ and control CD11cCre^+^ AMs ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Functional analysis of these genes with Ingenuity Pathway Analysis software revealed several pathways altered by the absence of VHL in AMs ([Figure S2](#mmc1){ref-type="supplementary-material"}B). We validated the expression of selected genes in pathways related to relevant features of AM physiology, such as cell cycle and liver X receptor/retinoid X receptor (LXR/RXR) activation, the latter being implicated in intracellular lipid sensing ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). The absence of VHL in AMs resulted in the reduced expression of genes involved in cell-cycle progression, such as cyclin B1 (*Ccnb1*), cyclin B2 (*Ccnb2)*, CDK1 (*Cdk1*), CD25c (*Cd25c*), and PLK3 (*Plk3*) ([Figure S2](#mmc1){ref-type="supplementary-material"}C \[top\]) and cell-cycle control, including BRCA1 (*Brca1*), CHEK1 (*Chek1*), and CHEK2 (*Chek2*), while the cell-cycle master regulators p53 (*Tp53*) and p21 (*Cdkn1a*) displayed similar expression levels ([Figure S2](#mmc1){ref-type="supplementary-material"}C \[bottom\]). Among those genes associated with the LXR/RXR activation pathway, upregulated transcript expression of LXRα (*Nr1h3*) and LXRβ (*Nr1h2*) genes ([Figure S2](#mmc1){ref-type="supplementary-material"}D) was confirmed. In accordance with this, we confirmed that there was an increased expression of genes involved in cholesterol efflux, such as the transporters ABCG1 (*Abcg1*) and apolipoprotein E (*ApoE*) and the lipoprotein remodeling enzyme PLTP (*Pltp*) ([Figure S2](#mmc1){ref-type="supplementary-material"}D). These results suggest that crucial distinctive features of AMs, such as proliferation and lipid handling, are affected by the absence of VHL.

Functional VHL Is Required for AM Self-Renewal Capacity {#sec2.4}
-------------------------------------------------------

We next investigated whether the absence of VHL affected the self-renewal capacity of AMs. We measured bromodeoxyuridine (BrdU) incorporation in BAL AMs cultured *in vitro* in the absence or presence of macrophage colony-stimulating factor (M-CSF) and GM-CSF, tissue-derived cytokines that contribute to the maintenance and proliferation of mature AMs ([@bib7]). VHL-deficient AMs proliferated significantly less than did control *Vhl*^fl/fl^ AMs both in the absence and presence of these cytokines ([Figure 3](#fig3){ref-type="fig"}A).Figure 3Cell-Intrinsic VHL Requirement for AM Self-Renewal and Terminal Maturation(A) *In vitro* BrdU assay of BAL AMs in complete RPMI (medium) or stimulated with recombinant mouse (rM)-CSF or recombinant granulocyte-macrophage (rGM)-CSF as indicated. Data are means ± SEMs and are representative of three experiments. n = 15--18 mice of each genotype. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, by unpaired Student's t test.(B and C) Ki67 staining in *ex vivo* BAL AMs. Representative flow cytometry plots (B) and frequencies of Ki67^+^ cells (C). Data are means ± SEMs and are representative of three experiments. n = 5 mice per genotype. ^∗∗∗^p \< 0.001 by unpaired Student's t test.(D and E) Mice were pulsed with BrdU for 3 weeks (1 mg intraperitoneally \[i.p.\] daily), and BrdU incorporation into BAL AMs was assessed 1 and 21 days after the last pulse. Representative flow cytometry plots (D); frequencies of BrdU^+^ AMs (left) and AM turnover (right) calculated as the ratio of frequencies of BrdU^+^ AMs at day 1 versus day 21 (E). Data are means ± SEMs and are representative of three experiments. n = 5 mice per genotype. ^∗∗∗^p \< 0.001; ns, not significant, by unpaired Student's t test.(F) Total lung AM number. Data are means ± SEMs and show a pool of two experiments representative of four performed. n = 5--6 per genotype. ^∗∗∗^p \< 0.001; ns, not significant, by unpaired Student's t test.(G) Flow cytometry plots and frequencies of DsRed^+^ (WT) and DsRed^−^ (Control *Vhl*^fl/fl^ or CD11cΔ*Vhl*) AMs (normalized to blood Ly6Chi monocyte frequency) from CD45.2^+^ AM fraction of BM chimeras.(H and I) Staining of Ki67 in *ex vivo* BAL AMs of the indicated genotypes from BM chimeras. Representative flow cytometry plots (H) and frequencies of Ki67^+^ BAL AMs (I).(J and K) Representative flow cytometry histograms for AM selected markers (red line for WT DsRed^+^ AMs or black line for Control *Vhl*^fl/fl^ or CD11cΔ*Vhl* AMs) in BAL AMs from the indicated BM chimera (J). Normalized geometric mean fluorescence intensity (GMFI) for AM selected markers (K).(G, I, and K) Data shown as means ± SEMs and are representative of three (G) or two (I) performed. n = 5--10 per group. ^∗∗∗^p \< 0.001; ns, not significant, by unpaired Student's t test.See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

To further investigate the potential role of VHL in AM self-renewal, we analyzed BAL AMs *ex vivo*. These experiments revealed significantly reduced Ki67 staining in VHL-deficient AMs than in control *Vhl*^fl/fl^ AMs ([Figures 3](#fig3){ref-type="fig"}B and 3C), suggesting impaired proliferation. We next tracked self-renewal *in vivo* by injecting BrdU intraperitoneally every day for 3 consecutive weeks. One day after the last pulse, VHL-deficient AMs from BAL showed lower BrdU incorporation than control *Vhl*^fl/fl^ AMs ([Figures 3](#fig3){ref-type="fig"}D and 3E), which is indicative of a decreased replication rate. In contrast, 21 days after the last pulse, BrdU labeling was similar in both genotypes ([Figures 3](#fig3){ref-type="fig"}D and 3E), which translated into a lower fold dilution of the incorporated BrdU in the absence of VHL ([Figure 3](#fig3){ref-type="fig"}F \[right\]). Despite the reduced turnover in VHL-deficient AMs, total lung AM numbers were similar in both genotypes ([Figure 3](#fig3){ref-type="fig"}F), suggesting that VHL-deficient AMs have a longer lifespan. Consistent with this, previous results showed increased primary macrophage survival under hypoxia ([@bib14]) and reduced apoptosis in *Phd3*^−/−^ BM-macrophages ([@bib21]).

AMs are replaced by BM-derived blood monocytes in lethal irradiation chimeras ([@bib7], [@bib26]). Therefore, we next asked whether *Vhl* deletion could also affect the replenishment of AMs after irradiation-induced cytoablation. We generated chimeric mice by intravenous adoptive transfer of BM cells from WT CD45.2^+^ DsRed mice (DsRed^+^) mixed at a 1:1 ratio with BM cells from either DsRed^−^ CD45.2^+^ CD11cΔ*Vhl* mice (WT:CD11cΔ*Vhl*) or DsRed^−^ CD45.2^+^ control *Vhl*^fl/fl^ (WT:control *Vhl*^fl/fl^) into lethally irradiated CD45.1^+^ WT recipient mice ([Figures 3](#fig3){ref-type="fig"}G--3K). After 47 days, the frequency of AMs was analyzed. Most BAL and lung AMs (after BAL) were of donor origin (CD45.2^+^) in both types of chimeras at this time point ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B) ([@bib7]). Notably, the frequency of CD11cΔ*Vhl* AMs in the BAL ([Figure 3](#fig3){ref-type="fig"}G) and the lung ([Figure S3](#mmc1){ref-type="supplementary-material"}C) of chimeric mice was significantly lower compared with control *Vhl*^fl/fl^ AMs, recapitulating the suboptimal reconstitution of the alveolar space by prolyl hydroxylase 3 (PHD3)-deficient AMs ([@bib23]). This result correlated with a significantly decreased proliferative capacity of BAL CD11cΔ*Vhl* AMs compared with WT AMs from co-transferred BM chimeras ([Figures 3](#fig3){ref-type="fig"}H and 3I). As a control, no differences were found in the potential of reconstitution of lung eosinophils from the different donors ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Moreover, CD11cΔ*Vhl* AMs showed an immature-like phenotype compared with WT AM counterparts ([Figures 3](#fig3){ref-type="fig"}J and 3K). Monocytic AM precursors only differentiate into mature AMs once they reach the lung ([@bib5], [@bib15], [@bib25]). Therefore, these results suggest that the absence of VHL driven by the CD11c promoter during AM differentiation intrinsically prevents their terminal phenotypic maturation and restrains their self-renewal capacity, decreasing their potential to reconstitute the alveolar niche in a context of competition with WT AMs. Because AM precursors come from oxygen-rich arterial blood, this result also supports the notion that VHL-mediated oxygen sensing is required but not sufficient for AM terminal differentiation.

VHL Contributes to Surfactant Handling by AMs {#sec2.5}
---------------------------------------------

Mice deficient for *Csf2* (GM-CSF) or *Csf2r* or with *Pparg* deletion in AMs show impaired AM maturation, resulting in low numbers of lung immature AMs that accumulate lipids intracellularly ([@bib13], [@bib15], [@bib19]). Immature AM-like cells from patients with surfactant accumulation and *Csf2*^−/−^ mice, as well as *Pparg*-deficient AMs, show an induction of LXR signaling ([@bib1], [@bib24]). These findings correlate with the LXR pathway activation predicted by our RNA-seq analysis ([Figure S2](#mmc1){ref-type="supplementary-material"}B) and with the increased expression of LXR-target genes implicated in lipid efflux in VHL-deficient AMs ([Figure S2](#mmc1){ref-type="supplementary-material"}D).

To quantify the lipid β-oxidation capacity of AMs, we measured the oxygen-consumption rate of BAL AMs in the presence of palmytoyl-coenzyme A (CoA) as a carbon source ([Figure 4](#fig4){ref-type="fig"}A). The basal respiration rate was significantly lower in AMs lacking VHL, indicating a reduced lipid oxidation capacity ([Figure 4](#fig4){ref-type="fig"}B), whereas the basal extracellular acidification rate was unaltered ([Figure 4](#fig4){ref-type="fig"}C). Unlike other models of impaired AM function, 3-month-old CD11cΔ*Vhl* mice did not show an increased accumulation of total protein in BAL supernatants ([Figure 4](#fig4){ref-type="fig"}D).Figure 4VHL Contributes to Surfactant Handling by AMs(A) OCR by BAL AMs in the presence of palmitoyl-CoA treated as seen in [Figure 2](#fig2){ref-type="fig"}D. Data are means ± SDs and are representative of three independent experiments. n = 6--7 mice of each genotype.(B and C) Basal respiratory rate (BRR) (B) and basal ECAR (C) of BAL AMs. Data represent three independent experiments. n = 6--7 mice per genotype. ^∗^p \< 0.05; ns, not significant, by ratio paired Student's t test.(D) Protein concentration in BAL from 3-month-old mice. Data are means ± SEMs and representative of three independent experiments. n = 5--9 mice per genotype. ns, not significant, by unpaired Student's t test.(E--G) 5 × 10^4^ AMs from control *Vhl*^fl/fl^ or CD11cΔ*Vhl* AMs were transferred intratracheally (i.t.) to *Csfr2b*^*−/−*^ mice. Scheme of the experiment (E). After 1.5 months, lung AM numbers (F) and BAL concentrations of total protein (G \[left\]) and SP-D (G \[right\]) were determined. Data represented as means ± SEMs of three pooled independent experiments. Additional control mice (*Csfr2b*^*−/−*^ and *Csfr2b*^*+/−*^) were added. n = 10--18 per group. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; ns, not significant, by one-way ANOVA and Bonferroni post hoc test. Only some relevant comparisons indicated.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

To determine whether the decreased ability to oxidize lipids of VHL-deficient AMs affected their therapeutic potential to degrade surfactant excess *in vivo*, we transplanted a limited number of AMs from BALs of CD11cΔ*Vhl* or control *Vhl*^fl/fl^ mice into *Csf2rb*^*−/−*^ mice, which lack mature AMs and spontaneously develop lung proteinosis ([Figures 4](#fig4){ref-type="fig"}E--4G) ([@bib13]). As a marker of disease severity, we measured total protein and surfactant protein D concentrations in BAL supernatants at 1.5 months after pulmonary macrophage transplantation ([Figure 4](#fig4){ref-type="fig"}E), a time point at which transferred WT AMs had removed surfactant nearly at the levels found in healthy mice ([Figure 4](#fig4){ref-type="fig"}G) ([@bib6], [@bib20]). Consistent with our earlier results ([Figure 3](#fig3){ref-type="fig"}F), AM engraftment in the lung was similar in both genotypes ([Figure 4](#fig4){ref-type="fig"}F). Transplanted AMs from CD11cΔ*Vhl* mice were less efficient than control *Vhl*^fl/fl^ mice at reversing surfactant accumulation in BAL from *Csf2rb*^*−/−*^ recipient mice BAL ([Figure 4](#fig4){ref-type="fig"}G). These results indicate that VHL contributes to the ability of AMs to oxidize lipids and to clear pulmonary surfactant *in vivo*.

In conclusion, we investigated whether AM adaptation to increased oxygen concentrations in the postnatal lung is relevant for AM function. Deletion of *Vhl* in AMs induced the expression of HIF target genes and altered their metabolic profile, leading to partial desensitization of AMs to oxygen. VHL-deficient AMs resembled immature-like AMs in terms of morphology and expression of maturation markers and have a limited self-renewal potential and altered transcriptional signature. Experiments of parabiosis and BM chimeras indicated that this is a cell-autonomous phenotype. These results suggest that besides lung tissue-specific factors, oxygen sensing is also needed for AM terminal differentiation. Functionally, VHL-deficient AMs showed defective therapeutic capacity to clear surfactant excess *in vivo*. Our data therefore suggest that an intact oxygen-sensing machinery is required for AM terminal differentiation, self-renewal, and functional capacity.

Experimental Procedures {#sec3}
=======================

Animals {#sec3.1}
-------

Mice were bred at CNIC under specific pathogen-free conditions. C57BL/6J-Crl mice (Charles River), *Csf2rb*^*−/−*^ mice ([@bib13]), and *Vhl*^fl/fl^ mice ([@bib11]) mated with CD11c-Cre BAC transgenic mice ([@bib2]) were used. B6/SJL (Ptprca Pepcb/BoyJ) mice expressing the CD45.1 allele and DsRed (Actb-DsRed.T3) mice were both acquired from the Jackson Laboratory. All of the animal procedures were approved by the Animal Ethics Committee of the CNIC, the Madrid Autonomous University Ethics Committee, and the Community of Madrid Authority, and were compliant with EU Directives 2010/63/EU and 2007/526/EC and with Spanish law under Real Decreto 1201/2005.

### Parabiosis {#sec3.1.1}

Parabiosis was performed by surgical attachment of the skin of two mice, which promoted the formation of microvasculature at the site of inflammation. CD11c-Cre^+^ *Vhl*^fl/fl^ and CD11c-Cre^−^ *Vhl*^fl/fl^ littermates were joined with B6/SJL, expressing the CD45.1 congenic marker to facilitate cell tracking after 1 month of parabiosis.

### BM Chimeras {#sec3.1.2}

B6/SJL mice expressing the CD45.1 congenic marker were lethally irradiated (12 Gy) and were reconstituted intravenously (i.v.) with 5 × 10^6^ cells of a 1:1 mixture of CD45.2^+^ WT DsRed^+^ BM cells and CD45.2^+^ CD11cΔ*Vhl* BM cells, or CD45.2^+^ WT DsRed^+^ BM cells and CD45.2^+^ control *Vhl*^fl/fl^ BM cells. Mice were analyzed 47 days after reconstitution.

AM Isolation {#sec3.2}
------------

Mice were sacrificed with a lethal dose of pentobarbital (Dolethal, Vetoquinol). Ten BALs per mouse were performed with a blunt fill needle (18G × 1.5; 1.2 × 40 mm, BD Safety Products), with 1 mL of PBS, 2.5 mM EDTA, and 2% fetal bovine serum (FBS, HyClone) (flow cytometry buffer) at 37°C. Samples were kept on ice until further processing. Red blood cell lysis was performed at room temperature (RT) for 3 min (RBC Lysis Buffer, Sigma-Aldrich). AMs were counted with a Neubauer chamber and cultured in RPMI 1640 (GIBCO) supplemented with 10% FBS plus 100 U/mL penicillin and 2 mM [l]{.smallcaps}-glutamine (complete RPMI) at 37°C and 5% CO~2~. Additional information can be found in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

RNA Isolation {#sec3.3}
-------------

Cell lysis was performed with buffer RLT (QIAGEN) containing 10 μm/mL β-mercaptoethanol, and RNA was isolated with the RNeasy Plus Mini Kit (QIAGEN). RNA concentration and integrity were determined with an Agilent 2100 Bioanalyzer (Caliper Life Science). Samples with RNA integrity values \>8 were further processed. cDNA was prepared using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Additional information can be found in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Metabolic Measurements {#sec3.4}
----------------------

Real-time oxygen-consumption rate (OCR) and extracellular acidification rate (ECAR) in AMs were determined with an XF-96 Extracellular Flux Analyzer (Seahorse Bioscience). BAL AMs were pooled from 6--7 mice per genotype. After red blood cell lysis, AMs were plated and incubated at 37°C without CO~2~ for 30 min before the Seahorse assay was run. Additional information can be found in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

BrdU Proliferation *In Vivo* {#sec3.5}
----------------------------

Four groups of mice (two groups of each genotype) were injected daily with 1 mg BrdU (Sigma-Aldrich) for 2 weeks. One day and 21 days after the last injection, two groups (one of each genotype) were sacrificed, and BAL AMs were analyzed for BrdU incorporation ([@bib7]). The ratio of frequencies of BrdU^+^ AMs at days 21 and 1 was calculated as a measurement of BrdU dilution for 21 days.

Pulmonary Macrophage Transplantation {#sec3.6}
------------------------------------

*Csf2rb*^*−/−*^ mice were pulmonary transplanted with 5 × 10^4^ BAL AM pools of control *Vhl*^fl/fl^ and CD11cΔ*Vhl* mice. Receptor mice were anesthetized with ketamine (Imalgene, Merial) and xylazine (Rompun, Bayer). Then, a small incision was made to partially expose the trachea and animals were intubated orotracheally with an i.v. catheter (22G, 0.9 × 25 mm; BD Insyte). Cells were inoculated with a pipette in 30 μL of PBS. The viability of AMs was \>90% after the last transplantation. Six weeks after transplantation, BAL was performed with 1 mL of PBS, centrifuged at 1,700 rpm for 5 min at RT, and supernatant was used to measure total protein and surfactant protein D (SP-D) concentrations. Additional information can be found in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Flow Cytometry {#sec3.7}
--------------

Stainings were performed at 4°C with the appropriate antibody (Ab) cocktail in cold flow cytometry buffer. Samples were processed with a Spectral Analyzer flow cytometer (SP6800, Sony), and data were analyzed with FlowJo software (Tree Star). Additional information can be found in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Bioinformatics Analysis {#sec3.8}
-----------------------

### GEO: [GSE60249](ncbi-geo:GSE60249){#intref0010} Array Data {#sec3.8.1}

Array data (CEL files) ([@bib15]) were downloaded from GEO and imported into R software with functions provided by the packages GEOquery and oligo. RMA (affy package) was used for data processing, normalization, and calculation of log2 transformed expression values. The array annotation database mogene11sttranscriptcluster.db was used to map expression values with their associated Ensembl gene IDs by selecting for each gene the transcript cluster with the highest median value across all of the samples. Additional information can be found in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

RNA-Seq {#sec3.9}
-------

BAL AMs were pooled from 5--7 mice per genotype and further purified by positive selection with anti-CD11c-microbeads (Miltenyi Biotec), following the manufacturer's instructions. A total of three pools per genotype were used for RNA-seq. Additional information can be found in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec3.10}
--------------------

Statistical comparisons were made with Prism version 7 (GraphPad Software, La Jolla, CA). Statistical tests are detailed in the figure legends. p values: ns, not significant; ^∗^p \< 0.05; ^∗∗^p \< 0.01; and ^∗∗∗^p \< 0.001.

Data and Software Availability {#app1}
==============================

The accession number for the RNA-seq data reported in this paper is GEO: [GSE108975](ncbi-geo:GSE108975){#intref0015}.

Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures and Figures S1--S3Document S2. Article plus Supplemental Information
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